OUR MISSION
The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
OFFERING
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report: Second Edition examines:
- Proprietary consumer insights on attitudes, uses and behaviours
- Deep dives into the most transformative compounds and companies
- Key regulations, transformative trends and commercial opportunities
HIGHLIGHTS AND INSIGHTS
PSYCH: What are the next steps
for investors?
PSYCH: What Lies Ahead?
The Future of Therapy
PSYCH: Psychedelics for
Substance Use
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
NEWS & INSIGHT
Psychedelic therapies could save billions of dollars
While a number of states have begun to legalise the medical use of certain psychedelics, widespread legalisation is set to start taking place from 2021 onwards.
Innovation in Psychedelics
This is a nascent industry, witnessing a flurry of commercial activity, including the founding of new companies, a number of IPO listings from established companies and a spate of M&A activity.
Consumer Attitudes
An estimated 150 million adults in the UK and US support the legalisation of psychedelics for medicinal use.
THE PSYCHEDELICS NEWSLETTER
Expert analysis and intelligence, straight to your inbox. Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.
ISSUES
Issue 07
Taking place 17-20 as part of Prohibition Partners LIVE, The PSYCH Symposium will bring together distinguished industry thought leaders, rising entrepreneurs and experienced policymakers.
Enjoy Issue 07 of The Psychedelics Newsletter, here.
Issue 08
Get the latest updates from across the psychedelics industry and read our exclusive interview with Ronan Levy, Executive Chairman of Field Trip Health.
Enjoy Issue 08 of The Psychedelics Newsletter, here.
